Consumer genetic testing company 23andMe will resume providing customers with health information, nearly two years after the U.S. Food and Drug Administration ordered the firm to stop doing so.
California-based 23andMe said Wednesday it now has FDA approval to provide health information based on genetic tests of customers' saliva samples, but will provide much less data than before, The New York Times reported.
The company also redesigned its website to make it easier for consumers to understand genetic information, and increased the price of the service from $99 to $199.
"Part of what we tried to do over the last two years is take advantage of being off the market to redesign the entire experience," Anne Wojcicki, co-founder and chief executive of 23andMe, told The Times.
In November 2013, the FDA told the company to stop providing health information until it could get agency approval by proving that its genetic test results were accurate.
Another California-based medical testing company called Theranos has been told by the FDA to stop using its method of taking blood samples from the finger instead of the arm until the FDA approves the device used, The Times reported.
